Back to top
more

bluebird bio (BLUE)

(Delayed Data from NSDQ)

$0.92 USD

0.92
5,160,078

+0.01 (1.13%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.93 +0.01 (0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More

by Zacks Equity Research

Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.

Zacks.com featured highlights include bluebird bio, Pros Holdings and Norwegian Cruise Line

by Zacks Equity Research

bluebird bio, Pros Holdings and Norwegian Cruise Line are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Stocks to Keep an Eye on for Superb Earnings Acceleration

by Tirthankar Chakraborty

Stocks like bluebird bio (BLUE), Pros Holdings (PRO), and Norwegian Cruise Line (NCLH) are worth a watch now because of solid earnings acceleration.

bluebird (BLUE) Stock Dives on Public Offering of Common Stock

by Zacks Equity Research

bluebird (BLUE) to issue secondary shares, diluting its current shareholder base. The company plans to raise $120 million in gross proceeds from this issue.

bluebird (BLUE) Updates on Progress With Zynteglo, 2023 Outlook

by Zacks Equity Research

bluebird bio, Inc. (BLUE) updates on the launch of gene therapy Zynteglo and provides cash burn guidance for 2023.

Ekta Bagri headshot

Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More

by Ekta Bagri

Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.

Implied Volatility Surging for bluebird bio (BLUE) Stock Options

by Zacks Equity Research

Investors need to pay close attention to bluebird bio (BLUE) stock based on the movements in the options market lately.

bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA

by Zacks Equity Research

bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.

bluebird (BLUE) Up on Positive Data on Gene Therapies at ASH

by Zacks Equity Research

bluebird (BLUE) gains on positive data on Zyntgelo in beta-thalassemia and lovo-cel in sickle cell disease.

Why Is Bluebird (BLUE) Up 6.2% Since Last Earnings Report?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

bluebird (BLUE) to Boost Cash With Priority Review Voucher Sale

by Zacks Equity Research

bluebird (BLUE) is set to sell one of its two priority review vouchers. This will strengthen its financial position as its existing cash balance is expected to exhaust by second-quarter 2023.

bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals

by Zacks Equity Research

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.

bluebird (BLUE) Q3 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research

While the commercial launch of Zynteglo is underway, bluebird's (BLUE) Q3 losses narrow but revenues miss estimates.

Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of 28.13% and 96.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Fstar Therapeutics, Inc. (FSTX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Fstar Therapeutics, Inc. (FSTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations

by Zacks Equity Research

Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.

bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line

by Zacks Equity Research

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.

Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD

by Zacks Equity Research

bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.

Global Blood (GBT) Up 1.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More

by Zacks Equity Research

Regulatory updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.

bluebird (BLUE) Up 101% in the Past Three Months: Here's Why

by Zacks Equity Research

bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.